- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00646152
Poly-ICLC to Prevent Respiratory Viral Infections A Safety Study
A Phase I Double-Blind, Placebo-Controlled, Dose-Escalating Study to Evaluate the Safety and Tolerability of Topical Nasal Poly-ICLC
This study will examine the safety of an experimental medication called Poly-ICLC, developed for preventing or reducing the severity of infections from influenza and other viruses acquired through the nose, mouth and lungs. The study is divided into two parts, in which Poly-ICLC is tested at different dose levels.
Healthy people between 18 and 70 years of age who have no chronic medical problems may be eligible for this study. Participants undergo the following procedures:
Part I
- Up to 7 days before Poly-ICLC administration: Medical history, physical examination and blood tests.
- Day 1: Nasal wash and Poly-ICLC administration. A small amount of salt water is placed into the front of the nose and then suctioned out. Poly-ICLC is then squirted into each nostril, one after the other, at a dose of 0.25, 0.5 or 1 mg. A small number of subjects are given a placebo (a solution with no active ingredient.) Subjects are observed in the clinic for 30 minutes after treatment.
- Day 2: Subjects receive a second nasal wash and repeat blood tests. They keep a diary card for 1 week, recording any drug side effects.
- Day 5: Subjects have repeat blood tests and a review of their diary card. The keep a diary card for another 3 weeks.
- Day 12: Subjects are contacted by phone to review their diary card.
- Day 28: Subjects are contacted by phone to review their diary card.
Part II
- Up to 7 days before Poly-ICLC administration: Medical history, physical examination and blood tests.
- Day 1: Nasal wash and Poly-ICLC administration. Same as above for Part I participants.
- Day 3: Subjects receive a second dose of medication and are observed again for 30 minutes.
- Day 4: Subjects receive a second nasal wash and repeat blood tests. They keep a diary card for 1 week, recording any drug side effects.
- Day 7: Subjects have repeat blood tests and a review of their diary card. The keep a diary card for another 3 weeks.
- Day 14: Subjects are contacted by phone to review their diary card.
- Day 28: Subjects are contacted by phone to review their diary card.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Polyinosinic-Polycytidylic acid stabilized with polylysine and carboxymethylcellulose (Poly-ICLC), a stabilized double stranded RNA (dsRNA) therapeutic viral mimic activating innate and adaptive immunity, has been in extensive preclinical and investigational clinical therapeutic use as an intramuscular and intravenous compound, most recently in oncology applications. Only recently have the mechanisms of action been more fully elucidated, including induction of interferons, cytokines, and chemokines. Recognizing this, the infectious disease applications have been pursued in in vitro and animal models. Intranasal Poly-ICLC provides protection against mortality in animal models for multiple highly pathogenic viruses including influenza, severe acute respiratory distress syndrome (SARS), smallpox and Ebola. As its effects are not dependant on knowing the causative virus, an effective compound that could be protective against several unknown respiratory viruses has significant clinical appeal. While there is clinical safety data for intramuscular (IM) Poly-ICLC, no clinical studies of nasal application of Poly-ICLC have been done.
This study is a phase I safety and pharmacokinetic trial of nasally applied Poly-ICLC. Human volunteers will be administered increasing doses of nasal Poly-ICLC, with serial evaluation of safety, tolerability, as well as exploratory markers of immune activation.
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Maryland
-
Bethesda, Maryland, United States, 20892
- National Institutes of Health Clinical Center, 9000 Rockville Pike
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
- INCLUSION CRITERIA:
Healthy volunteers age greater than or equal to 18 years and less than or equal to 70 years.
For 2 months prior to study drug administration, and through the last day of follow-up (Day 28), subjects must agree to:
- Not take any topical nasal medications (prescription or over the counter).
- Not receive live attenuated influenza vaccine (Flumist) or any other live attenuated intranasal vaccine (licensed or research).
- Not receive any other investigational medications or vaccines.
Females of child-bearing potential must agree to use one of the following methods of contraception for 4 weeks prior to date of screening evaluation through 4 weeks after study drug administration:
- Be surgically sterile.
- Use oral contraceptives or other form of hormonal birth control including hormonal vaginal rings or transdermal patches.
- Use an intra-uterine device (IUD).
- Use (by ensuring her male partner(s) uses) barrier contraception (condom) with a spermicide.
- Any other equivalent (as judged by the investigative team) methods of contraception.
EXCLUSION CRITERIA:
A medical history that includes any of the following:
Any chronic medical problem that requires daily topical nasal medications.
Prior nasal or sinus surgery (including trans-nasal approaches of other organs such as pituitary).
Allergic rhinitis, chronic sinusitis, or any other nasal inflammatory disease that requires daily intranasal or oral medication.
Any chronic pulmonary conditions including (but not limited to) asthma, chronic obstructive pulmonary disease, and chronic bronchitis.
Subjects with known hypersensitivity to interferons.
Any other medical history that in the opinion of the investigator significantly increases the risk associated with a Phase I drug (e.g. Patients with coronary heart disease, congestive heart failure, HIV, neuropsychiatric disorders, seizure disorder, autoimmune disease, hepatic decompensation, poorly controlled endocrine disorders (including poorly controlled diabetes, and actively hyper- or hypo-thyroid), hematological disorders (e.g. leukopenia, thrombocytopenia), ophthalmologic disorders (excluding errors or refractiveness) or other disorders for which symptoms of the condition could be similar to interferon-related toxicity or that might be exacerbated by interferon would be excluded. Patients with mild stable conditions, such as controlled hypertension, controlled diabetes, and osteoarthritis would be permitted to enroll.)
Any history of habitual intranasal cocaine or other intranasal recreational drug use at any time, or experimental intranasal concaine or other intranasal recreational drug use within the last 10 years. (e.g. a 50 year old who tried cocaine once at age 20 is acceptable for enrollment).
Women who are breast-feeding.
Positive urine or serum pregnancy test.
Participation in any research protocol that requires more than 100cc of blood to be given in any 6-week period of time.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Single Group Assignment
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
---|
Frequency of AE greater than or equal to grade 2 by subjects who receive drug
|
Secondary Outcome Measures
Outcome Measure |
---|
Intranasal cytokines, nasal NO production, inflammatory cells in nasal wash
|
Collaborators and Investigators
Publications and helpful links
General Publications
- Dushoff J, Plotkin JB, Viboud C, Earn DJ, Simonsen L. Mortality due to influenza in the United States--an annualized regression approach using multiple-cause mortality data. Am J Epidemiol. 2006 Jan 15;163(2):181-7. doi: 10.1093/aje/kwj024. Epub 2005 Nov 30.
- Hui DS, Sung JJ. Severe acute respiratory syndrome. Chest. 2003 Jul;124(1):12-5. doi: 10.1378/chest.124.1.12. No abstract available.
- Shortridge KF. Severe acute respiratory syndrome and influenza: virus incursions from southern China. Am J Respir Crit Care Med. 2003 Dec 15;168(12):1416-20. doi: 10.1164/rccm.2310005. No abstract available.
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Virus Diseases
- Infections
- Respiratory Tract Diseases
- Respiration Disorders
- Lung Diseases
- Infant, Newborn, Diseases
- DNA Virus Infections
- Lung Injury
- Infant, Premature, Diseases
- Poxviridae Infections
- Respiratory Distress Syndrome
- Respiratory Distress Syndrome, Newborn
- Acute Lung Injury
- Smallpox
- Physiological Effects of Drugs
- Immunologic Factors
- Interferon Inducers
- Poly ICLC
Other Study ID Numbers
- 080093
- 08-I-0093
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Influenza
-
Novartis VaccinesCompletedInfluenza | Seasonal Influenza | Human Influenza | Influenza Due to Unspecified Influenza VirusBelgium
-
Gamaleya Research Institute of Epidemiology and...CompletedInfluenza A | Influenza A Virus Infection | Influenza Epidemic | Influenza H5N1Russian Federation
-
Vanderbilt University Medical CenterHuman Vaccines ProjectCompletedVaccine Reaction | Influenza | Influenza, Human | Influenza A | Influenza Type B | Influenza A H3N2 | Influenza A H1N1United States
-
National Institute of Allergy and Infectious Diseases...CompletedInfluenza Immunisation | Avian InfluenzaUnited States
-
National Institute of Allergy and Infectious Diseases...Completed
-
National Institute of Allergy and Infectious Diseases...Completed
-
National Institute of Allergy and Infectious Diseases...CompletedInfluenza Immunisation | Avian InfluenzaUnited States
-
National Institute of Allergy and Infectious Diseases...CompletedInfluenza | Influenza Immunisation | Avian InfluenzaUnited States
-
National Institute of Allergy and Infectious Diseases...CompletedInfluenza Immunisation | Avian InfluenzaUnited States
-
National Institute of Allergy and Infectious Diseases...National Institutes of Health (NIH)CompletedInfluenza AUnited States
Clinical Trials on Poly-ICLC
-
Shanghai 10th People's HospitalHangzhou NeoVax Biotechnology Co. LTDRecruitingGlioma, Malignant | Antigen-specific Vaccines | Individualized TreatmentChina
-
Sidney Kimmel Comprehensive Cancer Center at Johns...National Cancer Institute (NCI)TerminatedBrain and Central Nervous System TumorsUnited States
-
Nevada Cancer InstituteCLL TopicsTerminatedB Cell Lymphoma | T Cell LymphomaUnited States
-
Rockefeller UniversityCompletedHealthy VolunteersUnited States
-
Nina BhardwajNational Institute of Allergy and Infectious Diseases (NIAID); National Institutes... and other collaboratorsCompletedHIV-1 Infected Adults With Chronic HIV-1 InfectionUnited States
-
Nina BhardwajOncovir, Inc.TerminatedMelanoma | Breast Cancer | Squamous Cell Carcinoma of the Head and Neck | Squamous Cell Carcinoma of the Skin | Sarcoma of the Skin | Basal Cell Cancer of the SkinUnited States
-
Medical University of South CarolinaCompletedA Study of Vaccination With Poly-ICLC and Dendritic Cells in Patients With Pancreatic AdenocarcinomaPancreatic Adenocarcinoma Non-resectableUnited States
-
Nventa Biopharmaceuticals CorporationUnknownCervical Intraepithelial NeoplasiaUnited States
-
Ashutosh Kumar TewariOncovir, Inc.Completed
-
Robert SchoenNational Cancer Institute (NCI)CompletedStudy of the MUC1 Peptide-Poly-ICLC Adjuvant Vaccine in Individuals With Advanced Colorectal AdenomaRisk for Colorectal CancerUnited States